Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-05-16
2006-05-16
Brumback, Brenda (Department: 1647)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S244000, C514S420000, C514S707000
Reexamination Certificate
active
07045531
ABSTRACT:
The invention relates to the identification of pharmacological agents to be used in the treatment of Alzheimer's disease and related pathological conditions. Methods and compositions for treatment of conditions caused by amyloidosis, Aβ-mediated ROS formation, or both, such as Alzheimer's disease, are disclosed.
REFERENCES:
patent: 5110493 (1992-05-01), Cherng-Chyi et al.
patent: 5242932 (1993-09-01), Gandy et al.
patent: 5310936 (1994-05-01), Regtop et al.
patent: 5357636 (1994-10-01), Dresdner, Jr. et al.
patent: 5373021 (1994-12-01), Marangos
patent: 5466680 (1995-11-01), Rudy
patent: 5523295 (1996-06-01), Fasman
patent: 5688516 (1997-11-01), Raad et al.
patent: 5688651 (1997-11-01), Solomon
patent: 5705401 (1998-01-01), Masters et al.
patent: 5707821 (1998-01-01), Rydel et al.
patent: 5721106 (1998-02-01), Maggio et al.
patent: 5927283 (1999-07-01), Abraham et al.
patent: 5980914 (1999-11-01), Gerolymatos
patent: 5994323 (1999-11-01), Gerolymatos
patent: 6001852 (1999-12-01), Gerolymatos
patent: 6323218 (2001-11-01), Bush et al.
patent: 40 04 978 (1991-08-01), None
patent: WO 92/18111 (1992-10-01), None
patent: WO 93/10459 (1993-05-01), None
patent: WO 93/24451 (1993-12-01), None
patent: WO 94/04167 (1994-03-01), None
patent: WO 94/27594 (1994-12-01), None
patent: WO 95/31199 (1995-11-01), None
patent: WO 96/07096 (1996-03-01), None
patent: WO 96/12544 (1996-05-01), None
patent: WO 96/28471 (1996-09-01), None
patent: WO 96/39144 (1996-12-01), None
patent: WO 97/01559 (1997-01-01), None
patent: WO 97/04794 (1997-02-01), None
patent: WO 97/09976 (1997-03-01), None
patent: WO 97/36885 (1997-10-01), None
patent: WO 98/06403 (1998-02-01), None
patent: WO 98/40071 (1998-09-01), None
patent: WO 99/09981 (1999-03-01), None
patent: WO 99/18432 (1999-04-01), None
Cherny et al. Treatment with a copper-zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer's disease transgenic mice. Neuron 30(3):665-676, 2001.
Cherny et al. Chelation and intercalation: complemetary properties in a compound for the treatment of Alzheimer's disease. J Struct Biol. 130(2-3): 209-216, 2000.
Kisilevsky et al. A beta amyloidogenesis: unique, or variation on a systemic theme? Crit Rev Biochem Mol Biol. 32(5):361-404, 1997.
Maury, CP. Molecular pathogenesis of beta-amyloidosis in Alzheimer's disease and other cerebral amyloidoses. Lab Invest 72(2);4-16, 1995.
Gnjec A, Fonte JA, Atwood C, Martins RN. Transition metal chelator therapy—a potential treatment for Alzheimer's disease? Front Biosci. 7:d1016-23, 2002.
Fonte et al. Journal of Alzheimer's Disease. 3(2): 209-219, 2001.
Gillmore et al. Amyloidosis: a review of recent diagnostic and therapeutic developments. Br J Haematol 99(2):245-56, 1997.
Schnabel, J. New alzheimer's therapy suggested. Science 260: 1719-1720, 1993.
Sigma Chemical Company. “Bathocuprione”, p. 149, catalog #B1000, 1995.
Goodman and Gilman. The Pharmacological Basis of Therapeutics. New York: McGraw-Hill, Inc. 1993, p. 5-6.
Assaf, S.Y and Chung, S. -H., “Release of endogenous Zn2−from brain tissue during activity,”Nature 308:734-736 (Apr. 1984).
Atwood, C.S. et al., “Dramatic Aggregation of Alzheimer Aβ by Cu(II) Is Induced by Conditions Representing Physiological Acidosis,”J. Biol. Chem. 273:12817-12826 (May 1998).
Bacon, P.A. et al., “Rheumatoid Disease, Amyloidosis and its treatment with Penicillamine,”Eur. J. Rheum. Inflamm. 2:70-74 (1979).
Barrow, C.J., and Zagorski, M.G., “Solution Structures of β Peptide and Its Constituent Fragments: Relation to Amyloid Deposition,”Science 253:179-182 (Jul. 1991).
Barrow, C.J., et al., “Solution Conformations and Aggregational Properties of Synthetic Amyloid β-Peptides of Alzheimer's Disease,”J. Mol. Biol. 225:1075-1093 (Jun. 1992).
Basun, H., et al., “Metals and trace elements in plasma and cerebrospinal fluid in normal ageing and Alzheimer's disease,”J. Neural Transm. [P-D Sect.] 3:231-258 (1991).
Behl, C., et al., “Hydrogen Peroxide Mediates Amyloid β Protein Toxicity,”Cell 77:817-827 (Jun. 1994).
Biaglow, J.E. and Kachur, A.V., “The Generation of Hydroxyl Radicals in the Reaction of Molecular Oxygen with Polyphosphate Complexes of Ferrous Ion,”Radiation Res. 148:181-187 (Aug. 1997).
Boado, R.J. et al., “Drug Delivery of Antisense Molecules to the Brain for Treatment of Alzheimer's Disease and Cerebral AIDS,”J. Pharm. Sci. 87(11):1308-1315 (Nov. 1998).
Borman, S., “Diverse Strategies Emerge For Diagnosing Alzheimer's Disease,”Chem. Eng. News272:33-34 (Jun. 1996).
Bruce, A.J. et al., “β-Amyloid toxicity in organotypic hippocampal cultures: Protection by EUK-8, a synthetic catalytic free radical scavenger,”Proc. Natl. Acad. Sci. USA 93:2312-2316 (Mar. 1996).
Burdick, D., et al., “Assembly and Aggregation Properties of Synthetic Alzheimer's A4/β Amyloid Peptide Analogs,”J. Biol. Chem. 267:546-554 (Jan. 1992).
Burns, J.A., et al., “Selective Reduction of Disulfides by Tris(2-carboxyethyl)phosphine,”J. Org. Chem. 56:2648-2650 (Apr. 1991).
Busciglio, J., and Yankner, B.A., “Apoptosis and increased generation of reactive oxygen species in Down's Syndrome neuronsin vitro,” nature 378:776-779 (Dec. 1995).
Bush, A.I., et al., “A Novel Zinc(II) Binding Site Modulates the Function of the βA4 Amyloid Protein Precursor of Alzheimer's Disease,”J. Biol. Chem. 268:16109-16112 (Aug. 1993).
Bush, A.I., et al., “Modulation of Aβ Adhesiveness and Secretase Site Cleavage by Zinc,”J. Biol. Chem. 269:12152-12158 (Apr. 1994).
Bush, A. I., et al., “The Amyloid β-Protein Precursor and Its Mammalian Homologues,”J. Biol. Chem. 269:26618-26621 (Oct. 1994).
Bush, A.I., et al., “Rapid Induction of Alzheimer Aβ Amyloid Formation by Zinc,”Science 265:1464-1467 (Sep. 1994).
Bush, A.I., et al., Response to “Zinc and Alzheimer's Disease,”Science 268:1920-1923 (Jun. 1995).
Butterfield, D.A., et al., “β-Amyloid Peptide Free Radical Fragments Initiate Synaptosmal Lipoperoxidation in a Sequence-Specific Fashion: Implications to Alzheimer's Disease,”Biochem. Biophys. res. Commun. 200:710-715 (Apr. 1994).
Butterfield, D.A., et al., “Aβ(25-35) Peptide Displays H2O2-Like Reactivity Towards Aqueous Fe2+, Nitroxide Spin Probes, and Synaptosomal Membrane Proteins,”Life Sci. 58:217-228 (1996).
Cherny, R.A. et al., “The Aggregation of Aβ in Human Brain is Mediated by Zinc,”Soc. for Neurosci. Abstracts 23:534 (Oct. 1997).
Chong, Y.-H., and Suh, Y.-H., “Aggregation of amyloid precursor proteins by alumunum in vitro,”Brain Research 670:137-141 (Jan. 1995).
Colaco, C.A.L.S., et al., “The role of the Maillard reaction in other pathologies: Alzheimer's disease,”Nephrol. Dial. Transplant. 11(Suppl. 5):7-12 (1996).
Connor, J.R. et al., “A Histochemical Study of Iron, Transferrin, and Feritin in Alzheimer's Diseased Brains,”J. Neurosci. Res. 31:75-83 (Jan. 1992).
Connor, J.R. et al., “Ceruloplasmin levels in the human superior temporal gyrus in aging and Alzheimer's disease,”Neursci. Lett. 159:88-90 (Sep. 1993).
Coyle, J.T., and Puttfarcken, P., “Oxidative Stress, Glutamate, and Neurodegenerative Disorders,”Science 262:689-695 (Oct. 1993).
Crapper McLachlan, D.R. et al., “Intramuscular desferrioxamine in patients with Alzheimer's disease,”Lancet 337:1304-1308 (Jun. 1991).
Cuajungco, M.P. and Lees, G.J., “Zinc and Alzheimer's disease: is there a direct link?”Brain Res. Rev. 23:219-236 (Apr. 1997).
Dedman, D.J. et al., “Iron and aluminum in relation to brain ferritin in normal individuals and Alzheimer's-disease and chronic renal-dialysis patients,”Biochem J. 287:509-514 (1992).
Deibel, M.A. et al., “Copper, iron, and zinc imbalances in severely d
Atwood Craig S.
Bush Ashley I.
Huang Xudong
Tanzi Rudolph E.
Brumback Brenda
Bunner Bridget E.
Sterne Kessler Goldstein & Fox P.L.L.C.
The General Hospital Corporation
LandOfFree
Composition comprising a metal chelator and a method of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Composition comprising a metal chelator and a method of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Composition comprising a metal chelator and a method of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3529592